var data={"title":"Metolazone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metolazone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6571?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metolazone-drug-information\" class=\"drug drug_general\">see &quot;Metolazone: Drug information&quot;</a> and <a href=\"topic.htm?path=metolazone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metolazone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195707\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zaroxolyn [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195708\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zaroxolyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060360\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diuretic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060354\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=metolazone-drug-information\" class=\"drug drug_general\">see &quot;Metolazone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Edema, refractory:</b> Children and Adolescents: Oral: Usual range: 0.2-0.4 mg/kg/day divided every 12-24 hours in combination with furosemide; the usual maximum dose in adults is 20 mg (Arnold, 1984; Nelson, 1996). According to the manufacturer, a lower dose of 0.05-0.1 mg/kg once daily has also been reported to result in weight loss and increase urine output in some pediatric patients.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Edema (renal disease):</b> Oral: Initial: 5-20 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Edema (heart failure):</b> Oral: Initial: 2.5 mg once daily; maximum daily dose: 20 mg (ACCF/AHA [Yancy, 2013]); <b>Note:</b> Dosing frequency may be adjusted based on patient-specific diuretic needs (eg, administration every other day or weekly) (HFSA [Lindenfeld, 2010]). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension: </b>Oral: Initial: 2.5-5 mg once daily; adjust dose as necessary to achieve maximum therapeutic effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use caution in patients with severe renal impairment, as most of the drug is excreted by the renal route and accumulation may occur. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Doing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; contraindicated in hepatic coma or precoma. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195682\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zaroxolyn: 2.5 mg [DSC], 5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195668\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060364\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food to decrease GI distress; administer early in day to avoid nocturia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24177879\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060363\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hypertension (alone or in combination with other antihypertensive agents); treatment of edema in CHF or renal diseases (including nephrotic syndrome and other states of impaired renal function) (All indications: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195746\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MetOLazone may be confused with metaxalone, methadone, methazolAMIDE, methIMAzole, methotrexate, metoclopramide, metoprolol, minoxidil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zaroxolyn may be confused with Zarontin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195744\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest discomfort, chest pain, necrotizing angiitis, orthostatic hypotension, palpitations, syncope, venous thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, depression, dizziness, drowsiness, fatigue, headache, neuropathy, paresthesia, restlessness, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin necrosis, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Glycosuria, gout, hypercalcemia, hyperglycemia, hyperuricemia, hypochloremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, hypovolemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, bloating, constipation, diarrhea, epigastric distress, nausea, pancreatitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia,  hemoconcentration, hypoplastic anemia, leukopenia, petechia, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, muscle spasm, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Transient blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195690\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to metolazone or any component of the formulation; anuria; hepatic coma or precoma. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for diuretics is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195672\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte disturbances: Severe hypokalemia and/or hyponatremia can occur rapidly following initial doses. Hypercalcemia, hypochloremic alkalosis, and/or hypomagnesemia can also occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Sensitivity reactions, including angioedema and bronchospasm, may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: Orthostatic hypotension may occur. Ethanol may potentiate orthostatic hypotensive effect of metolazone. Instruct patients to avoid ethanol during therapy. If taken concurrently, monitor for hypotensive effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Photosensitization may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Azotemia and oliguria may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout: Hyperuricemia  can occur and gout can be precipitated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with hypokalemia; correct before initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in severe renal disease. If azotemia and oliguria worsen during treatment in these patients, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interchangeability: Do not interchange Zaroxolyn with other formulations of metolazone that are not therapeutically equivalent at the same doses (eg, Mykrox, no longer available in the US).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: If given the morning of surgery, metolazone may render the patient volume depleted and blood pressure may be labile during general anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299705\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195677\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12604&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: Thiazide and Thiazide-Like Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Thiazide and Thiazide-Like Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May increase the serum concentration of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Thiazide and Thiazide-Like Diuretics may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: Thiazide and Thiazide-Like Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, granulocytopenia may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Diazoxide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipragliflozin: May enhance the adverse/toxic effect of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Thiazide and Thiazide-Like Diuretics may enhance the arrhythmogenic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Licorice: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Thiazide and Thiazide-Like Diuretics may decrease the excretion of Lithium. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the hypercalcemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, thiazide diuretics may decrease the excretion of calcium, and continued concomitant use can also result in metabolic alkalosis. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Promazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Thiazide and Thiazide-Like Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Toremifene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195678\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B  (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343861\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Metolazone crosses the placenta and appears in cord blood. Hypoglycemia, hypokalemia, hyponatremia, jaundice, and thrombocytopenia are reported as complications to the fetus or newborn following maternal use of thiazide diuretics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060359\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, renal function, blood pressure, body weight, fluid balance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195671\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water, as well as, potassium and hydrogen ions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195689\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Diuresis: ~60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &ge;24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Incomplete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 90%  to 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 6 to 20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (70% to 95% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4298008\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Metolazone 5 mg is approximately equivalent to hydrochlorothiazide 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195688\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 1 mg/mL oral suspension may be made by with tablets and one of three different vehicles (cherry syrup diluted 1:4 with simple syrup; a 1:1 mixture of Ora-Sweet and Ora-Plus; or a 1:1 mixture of Ora-Sweet SF and Ora-Plus). Crush twelve 10 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 60 days.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 0.25 mg/mL oral suspension may be made with tablets and a 1:1 mixture of methylcellulose 1% and simple syrup. Crush one 2.5 mg tablet in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 10 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 10 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;.  Stable for 91 days refrigerated (preferred), 28 days at room temperature in plastic, and 14 days at room temperature in glass.</p>\n    <div class=\"reference\">Nahata, MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004. </div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195693\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MetOLazone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $207.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $235.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $282.11</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038678\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Barolyn (FI);</li>\n      <li>Birobin (AT);</li>\n      <li>Diulo (AU, PT);</li>\n      <li>Merozolyn (BD);</li>\n      <li>Metenix 5 (GB, GR, IE, SG);</li>\n      <li>Metolaz (BD, IN);</li>\n      <li>Metos (KR);</li>\n      <li>Metoz (PH);</li>\n      <li>Mycros (TW);</li>\n      <li>Mykyo (TW);</li>\n      <li>Oldren (AR);</li>\n      <li>Pavedal (CL);</li>\n      <li>Rixia (TW);</li>\n      <li>Zaroxolyn (CH, DE, HK, IL, IT, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Arnold WC, &ldquo;Efficacy of Metolazone and Furosemide in Children With Furosemide-Resistant Edema,&rdquo; <i>Pediatrics</i>, 1984, 74(5):872-5. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metolazone-pediatric-drug-information/abstract-text/6493882 /pubmed\" target=\"_blank\" id=\"6493882 \">6493882 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo; <i>JAMA</i>, 2003, 289(19):2560-72. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metolazone-pediatric-drug-information/abstract-text/12748199/pubmed\" target=\"_blank\" id=\"12748199\">12748199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metolazone-pediatric-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wells TG, &ldquo;The Pharmacology and Therapeutics of Diuretics in the Pediatric Patient,&rdquo; <i>Pediatr Clin North Am</i>, 1990, 37(2):463-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metolazone-pediatric-drug-information/abstract-text/2184406 /pubmed\" target=\"_blank\" id=\"2184406 \">2184406 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metolazone-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12604 Version 132.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F195707\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F195708\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060360\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060354\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195682\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F195668\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060364\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F24177879\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060363\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F195746\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F195744\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195690\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195672\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299705\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195677\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195678\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3343861\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060359\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F195671\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F195689\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F4298008\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F195688\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F195693\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038678\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12604|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metolazone-drug-information\" class=\"drug drug_general\">Metolazone: Drug information</a></li><li><a href=\"topic.htm?path=metolazone-patient-drug-information\" class=\"drug drug_patient\">Metolazone: Patient drug information</a></li></ul></div></div>","javascript":null}